Skip to main content Skip to main menu
UF Health University of Florida
Community Health & Family Medicine College of Medicine
Donate Today
Jason Powell

Jason Powell, Pharm.D., BCACP

Clinical Assistant Professor

Department: Pharmacy Education and Practice
Business Phone: (352) 265-7015
Business Email: jpdrums@ufl.edu
CV: View Curriculum Vitae

About Jason Powell

Dr. Jason Powell, a Board Certified Ambulatory Care Pharmacist, was born and raised in Gainesville FL, with well-established roots within the Gainesville community. From a young age he has spent many fall Saturdays in Ben Hill Griffin Stadium along with countless other UF sporting events. He was able to spend his undergraduate years at UF marching in the drumline for the Pride of The Sunshine Gator Marching Band. After graduating from the University of Florida College of Pharmacy, Dr. Powell completed his residency with the UF College of Pharmacy specializing in anticoagulation, diabetes, hypertension, other chronic disease state management and academia. Starting in 2012, Dr. Powell began precepting 4th year pharmacy students completing their ambulatory care practice experience, while teaching within the working professional PharmD program precepting registered pharmacist seeking their Doctor of Pharmacy degree. In 2013, Dr. Powell was promoted to Clinical Assistant Professor with UF College of Pharmacy and was able to maintain his clinical practice site at UFHealth Family Medicine Eastside. In 2016, Dr. Powell was jointly appointment by the Colleges of Pharmacy and Medicine to become the clinical faculty pharmacist at both Family Medicine -Main st. and Eastside. With this appointment, Dr. Powell acted as clinical preceptor to the college of pharmacy fellowship program and managing editor for the college of pharmacy’s publication, Pharmanote. In 2019, he took on the additional role as the clinical preceptor to the PGY1 community pharmacy residency program. Dr. Powell continues to be active in research and scholarly works with a major focus on ambulatory care practice and newly approved medications. He continues to increase his teaching roles within the college of pharmacy while serving as the academic advisor for Doctor of Pharmacy students.

Accomplishments

Member
2009-Current · Kappa Psi Pharmaceutical Fraternity

Teaching Profile

Courses Taught
2018
PHA5165L Prof Skills Lab V
2018
PHA5763 Ambulatory Care Advanced Pharmacy Practice Experience
2018
PHA5781 Patient Care I
2018,2021-2023
PHA5876C Pt Care 8 Complex Pts
2015-2016
PHA5161L Pract Skills Lab I
2016,2024
PHA5878C Pt Care 3: Cv and Pulm
2013
PHA5108L Pharmaceu Skls Lab 1
2021-2024
PHA5166L Prof Skills Lab Vi
2021-2024
PHA5060 Ambulatory Care
2022-2024
PHA5788C Patient Care 6
2022-2023
PHA5163L Prac Skills Lab III
2023-2024
PHA5789C Patient Care 7
2024
PHA5561 Pathphys-Pt Assess II
2024
PHA5787C Pt Care 5: Endo

Board Certifications

  • Board certified ambulatory care pharmacist
    Board of Pharmacy Specialties

Research Profile

Dr. Powell’s research interests include hyperlipidemia medication, warfarin and diabetes care.

Publications

Academic Articles
2024
Partnering for Better Health: Using Continuous Glucose Monitoring and Clinical Pharmacist Collaboration to Improve Glycemic Control in Underserved Patients With Type 2 Diabetes.
Clinical therapeutics. 46(1):e7-e11 [DOI] 10.1016/j.clinthera.2023.10.005. [PMID] 38165024.
PubMed · Publisher’s Site
2024
Use of Dulaglutide, Semaglutide, and Tirzepatide in Diabetes and Weight Management.
Clinical therapeutics. 46(3):289-292 [DOI] 10.1016/j.clinthera.2023.12.014. [PMID] 38310052.
2 citations · PubMed · Publisher’s Site
2021
Bempedoic Acid: A New Tool in the Battle Against Hyperlipidemia.
Clinical therapeutics. 43(2):410-420 [DOI] 10.1016/j.clinthera.2020.12.001.
Publisher’s Site
2020
Brexanolone (Zulresso): Finally, an FDA-Approved Treatment for Postpartum Depression
Annals of Pharmacotherapy. 54(2):157-163 [DOI] 10.1177/1060028019873320.
Publisher’s Site
2020
Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19.
The Annals of pharmacotherapy. 54(8):827-831 [DOI] 10.1177/1060028020925558.
Publisher’s Site
2020
Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist.
Clinical therapeutics. 42(10):2100-2116 [DOI] 10.1016/j.clinthera.2020.07.017.
Publisher’s Site
2020
Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea.
The Annals of pharmacotherapy. 54(10):1016-1020 [DOI] 10.1177/1060028020915537.
Publisher’s Site
2019
Andexanet alfa: A Novel Factor Xa Inhibitor Reversal Agent.
The Annals of pharmacotherapy. 53(9):940-946 [DOI] 10.1177/1060028019835209. [PMID] 30813754.
8 citations · PubMed · Publisher’s Site
2019
Ertugliflozin: A New Option in the SGLT-2 Inhibitor Market for the Treatment of Type 2 Diabetes Mellitus.
The Annals of pharmacotherapy. 53(5):478-485 [DOI] 10.1177/1060028018818829. [PMID] 30522346.
4 citations · PubMed · Publisher’s Site
2016
Patient satisfaction with extended-interval warfarin monitoring.
Journal of thrombosis and thrombolysis. 42(4):486-93 [DOI] 10.1007/s11239-016-1385-9. [PMID] 27251646.
6 citations · PubMed · Publisher’s Site
2015
Feasibility of Extended-interval Follow-up for Patients Receiving Warfarin.
Cardiovascular therapeutics. 33(3):98-103 [DOI] 10.1111/1755-5922.12115. [PMID] 25786578.
9 citations · PubMed · Publisher’s Site
2015
Sodium-glucose cotransporter 2 inhibitors: the new option for diabetes mellitus management.
Southern medical journal. 108(2):82-90 [DOI] 10.14423/SMJ.0000000000000233. [PMID] 25688892.
8 citations · PubMed · Publisher’s Site
2014
Optimal management of type 2 diabetes in patients with increased risk of hypoglycemia.
Diabetes, metabolic syndrome and obesity : targets and therapy. 7:85-94 [DOI] 10.2147/DMSO.S48896. [PMID] 24623984.
16 citations · PubMed · Publisher’s Site
2013
Canagliflozin: a novel treatment option for type 2 diabetes.
Drug design, development and therapy. 7:1399-408 [DOI] 10.2147/DDDT.S48937. [PMID] 24285921.
14 citations · PubMed · Publisher’s Site
2013
Lorcaserin for weight management.
Diabetes, metabolic syndrome and obesity : targets and therapy. 6:209-16 [DOI] 10.2147/DMSO.S36276. [PMID] 23788837.
13 citations · PubMed · Publisher’s Site
2013
New and emerging pharmacologic therapies for type 2 diabetes, dyslipidemia, and obesity.
Clinical therapeutics. 35(1):A3-17 [DOI] 10.1016/j.clinthera.2012.12.012. [PMID] 23328274.
17 citations · PubMed · Publisher’s Site

Education

Pharm.D.
2012 · University of Florida

Contact Details

Phones:
Business:
(352) 265-7015
Emails:
Business:
jpdrums@ufl.edu
Addresses:
Business Mailing:
PO BOX 100486
PHARMACOTHERAPY & TRANSLATIONAL RESEARCH
 GAINESVILLE FL 326100486